Latest news and articles about الأمراض النادرة from NEX English
Bigen has announced its acquisition of Abilis Pharmaceuticals for <strong>$5.6 billion</strong>, aiming to expand its portfolio in immunology and rare diseases. This acquisition is one of the largest in the company's history.
Reports indicate that <strong>Sophia Scott</strong>, diagnosed with childhood dementia before her fourth birthday, may not live to see her sixteenth year. Sophia is currently struggling with the loss of her ability to speak and walk without assistance, posing significant challenges for her family.
David Vagincom and his team have launched the nonprofit initiative 'Every Cure', aimed at repurposing existing drugs to treat rare diseases. This innovative strategy challenges traditional scientific research models and opens new horizons in medicine.